Syros Pharmaceuticals to Present Preclinical Data on SY-1425 and CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting

Company’s Lead Drug Candidates Demonstrate Therapeutic Potential in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Other Acute Leukemias

CAMBRIDGE, Mass., March 16, 2016 – Syros Pharmaceuticals today announced that it will present new preclinical data on its lead program SY-1425 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as on its first-in-class selective cyclindependent kinase 7 (CDK7) inhibitor program in acute leukemias. These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 16-20 in New Orleans.

read more here

 


Leave a Reply

Your email address will not be published. Required fields are marked *


Home / Portfolio Company News / Syros Pharmaceuticals to Present Preclinical Data on SY-1425 and CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting